A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease

Abraham Lieberman, C. W. Olanow, K. Sethi, P. Swanson, C. H. Waters, S. Fahn, H. Hurtig, M. Yahr

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Objective: To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in a randomized, double-blind trial in PD patients with motor fluctuations. Background: L-dopa in the treatment of PD is associated with motor fluctuations, dyskinesia, and other adverse effects. The use of dopamine agonists in the treatment of PD delays recourse to L-dopa and thus delays the possibility of adverse effect onset. Methods: Ropinirole (n = 95) or placebo (n = 54) was added to L-dopa, and L-dopa was then reduced in a planned manner during the 6-month trial. Results: A significantly greater number of ropinirole patients were able to achieve a 20% or greater reduction in both L-dopa dose and in percent time spent 'off' compared with placebo (35.0% versus 13.0%; p = 0.003). The mean daily L-dopa dose was reduced significantly with ropinirole treatment (242 mg versus 51 mg; p < 0.001) as was the percent awake time spent 'off' (11.7% versus 5.1%; p = 0.039). There was no difference in the percent of patients who withdrew because of adverse effects (15.8% on ropinirole versus 16.7% on placebo). Conclusions: Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations.

Original languageEnglish (US)
Pages (from-to)1057-1062
Number of pages6
JournalNeurology
Volume51
Issue number4
DOIs
StatePublished - Jan 1 1998

Fingerprint

Levodopa
Multicenter Studies
Parkinson Disease
Dopamine Agonists
Placebos
Therapeutics
ropinirole
Dyskinesias

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., ... Yahr, M. (1998). A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology, 51(4), 1057-1062. https://doi.org/10.1212/WNL.51.4.1057

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. / Lieberman, Abraham; Olanow, C. W.; Sethi, K.; Swanson, P.; Waters, C. H.; Fahn, S.; Hurtig, H.; Yahr, M.

In: Neurology, Vol. 51, No. 4, 01.01.1998, p. 1057-1062.

Research output: Contribution to journalArticle

Lieberman, A, Olanow, CW, Sethi, K, Swanson, P, Waters, CH, Fahn, S, Hurtig, H & Yahr, M 1998, 'A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease', Neurology, vol. 51, no. 4, pp. 1057-1062. https://doi.org/10.1212/WNL.51.4.1057
Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology. 1998 Jan 1;51(4):1057-1062. https://doi.org/10.1212/WNL.51.4.1057
Lieberman, Abraham ; Olanow, C. W. ; Sethi, K. ; Swanson, P. ; Waters, C. H. ; Fahn, S. ; Hurtig, H. ; Yahr, M. / A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. In: Neurology. 1998 ; Vol. 51, No. 4. pp. 1057-1062.
@article{3f00efb84666464db2abe0df2e06bb4e,
title = "A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease",
abstract = "Objective: To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in a randomized, double-blind trial in PD patients with motor fluctuations. Background: L-dopa in the treatment of PD is associated with motor fluctuations, dyskinesia, and other adverse effects. The use of dopamine agonists in the treatment of PD delays recourse to L-dopa and thus delays the possibility of adverse effect onset. Methods: Ropinirole (n = 95) or placebo (n = 54) was added to L-dopa, and L-dopa was then reduced in a planned manner during the 6-month trial. Results: A significantly greater number of ropinirole patients were able to achieve a 20{\%} or greater reduction in both L-dopa dose and in percent time spent 'off' compared with placebo (35.0{\%} versus 13.0{\%}; p = 0.003). The mean daily L-dopa dose was reduced significantly with ropinirole treatment (242 mg versus 51 mg; p < 0.001) as was the percent awake time spent 'off' (11.7{\%} versus 5.1{\%}; p = 0.039). There was no difference in the percent of patients who withdrew because of adverse effects (15.8{\%} on ropinirole versus 16.7{\%} on placebo). Conclusions: Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations.",
author = "Abraham Lieberman and Olanow, {C. W.} and K. Sethi and P. Swanson and Waters, {C. H.} and S. Fahn and H. Hurtig and M. Yahr",
year = "1998",
month = "1",
day = "1",
doi = "10.1212/WNL.51.4.1057",
language = "English (US)",
volume = "51",
pages = "1057--1062",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease

AU - Lieberman, Abraham

AU - Olanow, C. W.

AU - Sethi, K.

AU - Swanson, P.

AU - Waters, C. H.

AU - Fahn, S.

AU - Hurtig, H.

AU - Yahr, M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Objective: To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in a randomized, double-blind trial in PD patients with motor fluctuations. Background: L-dopa in the treatment of PD is associated with motor fluctuations, dyskinesia, and other adverse effects. The use of dopamine agonists in the treatment of PD delays recourse to L-dopa and thus delays the possibility of adverse effect onset. Methods: Ropinirole (n = 95) or placebo (n = 54) was added to L-dopa, and L-dopa was then reduced in a planned manner during the 6-month trial. Results: A significantly greater number of ropinirole patients were able to achieve a 20% or greater reduction in both L-dopa dose and in percent time spent 'off' compared with placebo (35.0% versus 13.0%; p = 0.003). The mean daily L-dopa dose was reduced significantly with ropinirole treatment (242 mg versus 51 mg; p < 0.001) as was the percent awake time spent 'off' (11.7% versus 5.1%; p = 0.039). There was no difference in the percent of patients who withdrew because of adverse effects (15.8% on ropinirole versus 16.7% on placebo). Conclusions: Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations.

AB - Objective: To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in a randomized, double-blind trial in PD patients with motor fluctuations. Background: L-dopa in the treatment of PD is associated with motor fluctuations, dyskinesia, and other adverse effects. The use of dopamine agonists in the treatment of PD delays recourse to L-dopa and thus delays the possibility of adverse effect onset. Methods: Ropinirole (n = 95) or placebo (n = 54) was added to L-dopa, and L-dopa was then reduced in a planned manner during the 6-month trial. Results: A significantly greater number of ropinirole patients were able to achieve a 20% or greater reduction in both L-dopa dose and in percent time spent 'off' compared with placebo (35.0% versus 13.0%; p = 0.003). The mean daily L-dopa dose was reduced significantly with ropinirole treatment (242 mg versus 51 mg; p < 0.001) as was the percent awake time spent 'off' (11.7% versus 5.1%; p = 0.039). There was no difference in the percent of patients who withdrew because of adverse effects (15.8% on ropinirole versus 16.7% on placebo). Conclusions: Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations.

UR - http://www.scopus.com/inward/record.url?scp=0031664919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031664919&partnerID=8YFLogxK

U2 - 10.1212/WNL.51.4.1057

DO - 10.1212/WNL.51.4.1057

M3 - Article

C2 - 9781529

AN - SCOPUS:0031664919

VL - 51

SP - 1057

EP - 1062

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -